ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells
Open Access
- 10 February 2003
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 88 (3) , 396-400
- https://doi.org/10.1038/sj.bjc.6600735
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- High-Dose Chemotherapy in the Treatment of Relapsed Osteosarcoma: An Italian Sarcoma Group StudyJournal of Clinical Oncology, 2002
- Tyrosine kinases and gastric cancerOncogene, 2000
- A novel germ line juxtamembrane Met mutation in human gastric cancerOncogene, 2000
- State-of-the-art chemotherapy for advanced breast cancer.2000
- Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy.2000
- HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test.2000
- Herceptin (trastuzamab) in advanced breast cancerCancer Treatment Reviews, 2000
- Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit thein vitro growth of human head and neck cancer cells and cause rapid tumor regressionin vivoInternational Journal of Cancer, 2000
- Expression of HER2/erbB-2 Correlates With Survival in OsteosarcomaJournal of Clinical Oncology, 1999
- Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors.1992